Lv41
490 积分 2021-12-30 加入
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes
5小时前
已完结
Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations
6小时前
求助中
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS)
8小时前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
2个月前
已完结
Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia
2个月前
已完结
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
2个月前
已完结
P-230: Preclinical and translational biomarker analysis to support further clinical development and dose optimization of mezigdomide (MEZI; CC-92480) in combination with either bortezomib or carfilzomib
3个月前
已完结
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
3个月前
已关闭
Tazemetostat for Advanced Epithelioid Sarcoma: Current Status and Future Perspectives
3个月前
已完结
OA-41 Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
3个月前
已完结
皖公网安备34019202002308
